174 related articles for article (PubMed ID: 17010152)
1. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
Leik CE; Su EJ; Nambi P; Crandall DL; Lawrence DA
J Thromb Haemost; 2006 Dec; 4(12):2710-5. PubMed ID: 17010152
[TBL] [Abstract][Full Text] [Related]
2. Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.
Brandal S; Blake CM; Sullenger BA; Fortenberry YM
Nucleic Acid Ther; 2011 Dec; 21(6):373-81. PubMed ID: 22103403
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation.
Ji Y; Weng Z; Fish P; Goyal N; Luo M; Myears SP; Strawn TL; Chandrasekar B; Wu J; Fay WP
Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2167-2175. PubMed ID: 27659097
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.
Wu J; Strawn TL; Luo M; Wang L; Li R; Ren M; Xia J; Zhang Z; Ma W; Luo T; Lawrence DA; Fay WP
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):111-20. PubMed ID: 25378411
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices.
Garg N; Goyal N; Strawn TL; Wu J; Mann KM; Lawrence DA; Fay WP
J Thromb Haemost; 2010 Aug; 8(8):1847-54. PubMed ID: 20492459
[TBL] [Abstract][Full Text] [Related]
6. Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1.
Redmond EM; Cullen JP; Cahill PA; Sitzmann JV; Stefansson S; Lawrence DA; Okada SS
Circulation; 2001 Jan; 103(4):597-603. PubMed ID: 11157728
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin.
Luo M; Ji Y; Luo Y; Li R; Fay WP; Wu J
J Thromb Haemost; 2017 Dec; 15(12):2451-2460. PubMed ID: 29028290
[TBL] [Abstract][Full Text] [Related]
8. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
Bajou K; Masson V; Gerard RD; Schmitt PM; Albert V; Praus M; Lund LR; Frandsen TL; Brunner N; Dano K; Fusenig NE; Weidle U; Carmeliet G; Loskutoff D; Collen D; Carmeliet P; Foidart JM; Noël A
J Cell Biol; 2001 Feb; 152(4):777-84. PubMed ID: 11266468
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.
McMahon GA; Petitclerc E; Stefansson S; Smith E; Wong MK; Westrick RJ; Ginsburg D; Brooks PC; Lawrence DA
J Biol Chem; 2001 Sep; 276(36):33964-8. PubMed ID: 11441025
[TBL] [Abstract][Full Text] [Related]
10. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin.
Isogai C; Laug WE; Shimada H; Declerck PJ; Stins MF; Durden DL; Erdreich-Epstein A; DeClerck YA
Cancer Res; 2001 Jul; 61(14):5587-94. PubMed ID: 11454712
[TBL] [Abstract][Full Text] [Related]
12. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.
Stefansson S; Lawrence DA
Nature; 1996 Oct; 383(6599):441-3. PubMed ID: 8837777
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2004 Dec; 12(6):1155-62. PubMed ID: 15547731
[TBL] [Abstract][Full Text] [Related]
14. Fibrillar collagen regulation of plasminogen activator inhibitor-1 is involved in altered smooth muscle cell migration.
Tanaka S; Koyama H; Ichii T; Shioi A; Hosoi M; Raines EW; Nishizawa Y
Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1573-8. PubMed ID: 12377732
[TBL] [Abstract][Full Text] [Related]
15. The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin.
Stefansson S; Su EJ; Ishigami S; Cale JM; Gao Y; Gorlatova N; Lawrence DA
J Biol Chem; 2007 May; 282(21):15679-89. PubMed ID: 17403662
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor.
Gorlatova NV; Cale JM; Elokdah H; Li D; Fan K; Warnock M; Crandall DL; Lawrence DA
J Biol Chem; 2007 Mar; 282(12):9288-96. PubMed ID: 17276980
[TBL] [Abstract][Full Text] [Related]
17. Ethanol inhibits pulse pressure-induced vascular smooth muscle cell migration by differentially modulating plasminogen activator inhibitor type 1, matrix metalloproteinase-2 and -9.
Cullen JP; Sayeed S; Kim Y; Theodorakis NG; Sitzmann JV; Cahill PA; Redmond EM
Thromb Haemost; 2005 Sep; 94(3):639-45. PubMed ID: 16268483
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis.
Chen SC; Henry DO; Reczek PR; Wong MK
Mol Cancer Ther; 2008 May; 7(5):1227-36. PubMed ID: 18483310
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1).
Schneider DJ; Hayes M; Wadsworth M; Taatjes H; Rincón M; Taatjes DJ; Sobel BE
J Histochem Cytochem; 2004 Aug; 52(8):1091-9. PubMed ID: 15258185
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic activity of beta-eudesmol in vitro and in vivo.
Tsuneki H; Ma EL; Kobayashi S; Sekizaki N; Maekawa K; Sasaoka T; Wang MW; Kimura I
Eur J Pharmacol; 2005 Apr; 512(2-3):105-15. PubMed ID: 15840394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
